Aptamino, Inc. is a biotechnology company headquartered in Cambridge, Massachusetts, that focuses on oral antibody delivery utilizing protein design. The privately held, minority- and woman-owned small business has received funding awards from organizations such as DARPA.
Subscribe to see Aptamino, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Aptamino, Inc. is a biotechnology company headquartered in Cambridge, United States. Its most recent funding round raised $8M in March 2026. Xcout tracks 2 named people at Aptamino, Inc., including Isaac Lutz (Executive Officer).
As of 16 November 2026. Source: Xcout Intel.
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| SEC Form D filing | $8M | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
A few of Aptamino, Inc.'s closest competitors — see the full list of competitors and alternatives →
Senda Biosciences is a biotechnology company focused on harnessing nature to program novel medicines, headquartered in Cambridge, Massachusetts.
Expedition Medicines, Inc. is a biotechnology company founded in 2022 and headquartered in Cambridge, Massachusetts, focused on generatively designing novel drugs targeting specific proteins.
Stipple Bio, Inc. is a private biotechnology company headquartered in Cambridge, Massachusetts, United States, focused on harnessing epitope-level precision in therapeutics.
Crossbow Therapeutics is a privately held biotechnology company founded in 2021 and headquartered in Cambridge, Massachusetts. The company develops potent antibody therapeutics aimed at expanding treatment options and combating cancer.
Guardian Therapeutics, LLC is a biotechnology company that researches and develops aptamer-based therapeutics and drug conjugates. The company engineers drug-like aptamers for targeted treatments across multiple therapeutic areas, including hematology, gastroenterology, dermatology, and oncology.
Adaptin Bio is a biotechnology company developing a proprietary drug delivery platform designed to enhance the transfer of therapeutics across biological barriers into the brain and other targeted tissues. Its lead technology, the Brain Bispecific T cell Engager (BRiTE) platform, manipulates the human immune system to target diseases in oncology, central nervous system disorders, autoimmune conditions, and cardiovascular markets.
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Something wrong or missing about Aptamino, Inc.? Suggest a correction · Work at Aptamino, Inc.? Claim this profile
Post the link and the card appears automatically — each network fetches the image itself.